Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 45% Off
/Free Sign Up
 0
✨ It’s Here: WarrenAI - Your Personal Financial AI Researcher >>>
Try Now
Close

Milestone Pharmaceuticals Inc (MIST)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Milestone Pharmaceuticals's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1.060 +0.050    +4.95%
15:59:59 - Closed. Currency in USD
After Hours
1.100
+0.040
+3.77%
16:01:32 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 2,431,330
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.978 - 1.085
Milestone Pharmaceuticals 1.060 +0.050 +4.95%

Milestone Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Milestone Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

33

Equity Type

ORD

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Contact Information

Address 1111 Dr. Frederik-Philips Boulevard Suite 420
Montreal, H4M 2X6
Canada
Phone 514-336-0444
Fax -
Web www.milestonepharma.com

Top Executives

Name Age Since Title
Philip T. Sager 69 2020 Chief Medical Advisor & Member of the Scientific Advisory Board
John DiMarco - - Member of the Scientific Advisory Board
Harry A. Kopelman - - Member of the Scientific Advisory Board
Philippe Douville 63 2005 Founder, Strategic Advisor & Member of Scientific Advisory Board
Albert L. Waldo - - Member of the Scientific Advisory Board
Harry Jefferson Leighton 79 - Member of the Scientific Advisory Board
Michael John Tomsicek 59 2019 Independent Non-Executive Director
Seth H. Z. Fischer 69 2023 Independent Non-Executive Director
Stuart M. Duty 56 2024 Independent Director
Daniel R. Omstead 72 2017 Observer
Joseph C. Papa 69 2024 Independent Non-Executive Director
John Camm - - Member of the Scientific Advisory Board
Jean-Yves Le Heuzey - - Member of the Scientific Advisory Board
Paul Dorian - - Member of the Scientific Advisory Board
Lisa M. Giles 66 2020 Independent Non-Executive Director
Joseph G. Oliveto 57 2017 CEO, President & Director
Peter R. Kowey - - Member of the Scientific Advisory Board
Robert James Wills 71 2020 Independent Chairman of the Board
Andrew R. Saik 56 2024 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

MIST Comments

Write your thoughts about Milestone Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Anthony Gautier
Anthony Gautier Apr 03, 2025 3:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data. However, the firm expects the product's launch to be delayed until the first half of 2026.
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Apr 01, 2025 9:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The drug will get approved, just going through formality, company asked for a Class A review within 30 days...this will expedite the review and ruling.....jmo
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Mar 31, 2025 11:20AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
buyer time
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Mar 31, 2025 9:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Within 30 days this will be on track
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Mar 29, 2025 4:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The Drug has proven effective and eventually will get approved after this inspection I believe, therefore hold and even adding 5k shares at this price level.....jmo
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Mar 28, 2025 2:57PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Eventually this drug WILL be approved...Great buying opportunity.....The FDA’s concerns did not pertain to the clinical safety or efficacy of etripamil but rather focused on additional information required on nitrosamine impurities and an inspection of a facility involved in release testing for the drug, which recently underwent a change in ownership. This facility inspection is necessary to ensure compliance with Current Good Manufacturing Practices.
Reply
0 0
Report
Anthony Gautier
Anthony Gautier Mar 28, 2025 2:43PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The FDA is doing their job, with denying the drug, it's all precautionary measures that will cause a delay of a STILL promising drug. I think it's a great buying opportunity..Thanks please do your own due diligence and invest wisely
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Mar 28, 2025 2:38PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
analyst news, H.C. Wainwright maintained a Buy rating on Milestone, with a $25 price target, citing the potential approval of CARDAMYST by March 2025 as a significant driver. The firm highlighted the drug’s potential to transform the management of paroxysmal supraventricular tachycardia and its broader market opportunities.
Reply
1 0
Report
Andrew Gordon
Andrew Gordon Mar 28, 2025 10:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$MIST I think that there will be a class action law suit. Why didn't management address the nitrosamine issue after the FDA guidance on nitrosamines in September? Why didn't management discuss the change of ownership of the manufacturer with the FDA?
Reply
0 0
Report
Anthony Gautier
Anthony Gautier Mar 28, 2025 10:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Andrew Gordon, why can't you just calm down, there's no need to have a class action suit as this seems to only implicate a lack of follow through that was I'm sure unintentionally caused. The FDA is taking care of what's necessary without denying the product just the safety requirements which is the problem. I believe eventually this will be approved since it's a corrective measure that can be satisfied if any. Chill....patience is needed..
Reply
1 0
Report
Anthony Gautier
Anthony Gautier Mar 28, 2025 10:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
While the stock will likely experience near-term pressure, the preservation of the clinical efficacy and safety profile keeps the core investment thesis intact. This appears to be a delay rather than a derailment of etripamil's prospects, though the extended timeline increases financial risk and uncertainty. The coming Type A meeting will be crucial in determining the length of the delay and associated cash
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Apple
Continue with Google
or
Sign up with Email